Home・Aktien・Merck & Co Inc.

Merck & Co Inc.

Open

BrancheGesundheitswesen

127.89 0.42

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

125.21

Max

129.94

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.2B -4.2B
Verkäufe	-114M 16B
KGV Branchendurchschnitt	36.834 64.641
EPS	-1.28
Dividendenrendite	2.5
Gewinnspanne	-26.053
Angestellte	73,000
EBITDA	-6.4B -2B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+7.18% upside

Dividenden
By Acuity
Dividendenrendite Branchendurchschnitt	2.50% 2.31%
Nächstes Ergebnis	4. Aug. 2026
Nächste Dividendenausschüttung	7. Okt. 2026
Nächstes Ex-Dividendendatum	15. Sept. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	35B 307B
Vorheriger Eröffnungskurs	127.47
Vorheriger Schlusskurs	127.89

Nachrichtenstimmung

By Acuity

21%

79%

48 / 340 Ranking in Healthcare

Merck & Co Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Merck & Co Inc. Prognose

Kursziel

By TipRanks

7.18% Vorteil

12-Monats-Prognose

Durchschnitt 136.94 USD 7.18%

Hoch 155 USD

Tief 100 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Merck & Co Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

Buy

Halten

Sell

Basierend auf 18 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Merck & Co Inc. – Dist abgegeben haben.

Stimmung

By Acuity

48 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.